| 臺大學術典藏 |
2011 |
Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis
|
Lin S.-L.;Chang F.-C.;Schrimpf C.;Chen Y.-T.;Wu C.-F.;Wu V.-C.;Chiang W.-C.;Kuhnert F.;Kuo C.J.;Yung-Ming Chen;Wu K.-D.;Tsai T.-J.;Duffield J.S.; Lin S.-L.; Chang F.-C.; Schrimpf C.; Chen Y.-T.; Wu C.-F.; Wu V.-C.; Chiang W.-C.; Kuhnert F.; Kuo C.J.; YUNG-MING CHEN; Wu K.-D.; Tsai T.-J.; Duffield J.S. |
| 臺大學術典藏 |
2020-12-24T08:38:29Z |
Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis
|
WEN-CHIH CHIANG; Wu V.-C.; Chen Y.-T.; Wu C.-F.; Schrimpf C.; Chang F.-C.; Lin S.-L.; Lin S.-L.;Chang F.-C.;Schrimpf C.;Chen Y.-T.;Wu C.-F.;Wu V.-C.;Wen-Chih Chiang;Kuhnert F.;Kuo C.J.;Chen Y.-M.;Wu K.-D.;Tsai T.-J.;Duffield J.S.; Duffield J.S.; Kuhnert F.; Kuo C.J.; Chen Y.-M.; Wu K.-D.; Tsai T.-J. |
| 臺大學術典藏 |
2020-12-23T02:58:02Z |
Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis
|
Tsai T.-J.; Wu K.-D.; Chen Y.-M.; Kuo C.J.; Kuhnert F.; Chiang W.-C.; Lin S.-L.;Chang F.-C.;Schrimpf C.;Chen Y.-T.;Wu C.-F.;Vin-Cent Wu;Chiang W.-C.;Kuhnert F.;Kuo C.J.;Chen Y.-M.;Wu K.-D.;Tsai T.-J.;Duffield J.S.; Lin S.-L.; Chang F.-C.; Schrimpf C.; Chen Y.-T.; Wu C.-F.; VIN-CENT WU; Duffield J.S. |
| 國立臺灣大學 |
2011 |
Targeting Energy Metabolic and Oncogenic Signaling Pathways in Triple- Negative Breast Cancer by a Novel Adenosine Monophosphate-Activated Protein Kinase (Ampk) Activator
|
顧記華; 楊小青; 陳慶士; GUH, JIH-HWA; YANG, HSIAO-CHING; CHEN, CHING-SHIH |
| 臺大學術典藏 |
2021-06-02T05:43:48Z |
Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator
|
Lee K.-H.; Hsu E.-C.; JIH-HWA GUH; Yang H.-C.; Wang D.; Kulp S.K.; Shapiro C.L.; Chen C.-S. |
| 臺大學術典藏 |
2021-06-04T03:09:10Z |
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease
|
Kao Y.-H.;Lin M.-S.;Chen C.-M.;Wu Y.-R.;Chen H.-M.;Lai H.-L.;Chern Y.;Chun-Jung Lin; Kao Y.-H.; Lin M.-S.; Chen C.-M.; Wu Y.-R.; Chen H.-M.; Lai H.-L.; Chern Y.; CHUN-JUNG LIN |
| 臺北醫學大學 |
2006 |
Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia–Pacific region
|
劉興璟; Liu HE; Lim KH; Huang MJ; Huang BS |
| 國立臺灣大學 |
2013 |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
|
Tsai, Yu-Chieh; Yeh, Chih-Hsien; Tzen, Kai-Yuan; Ho, Pei-Yin; Tuan, Tsung-Fan; Pu, Yeong-Shiau; Cheng, Ann-Lii; Cheng, Jason Chia-Hsien; 蒲永孝; 曾凱元; 鄭安理; 成佳憲; 蔡育傑; 何蓓茵 |
| 臺大學術典藏 |
2021-02-02T00:46:32Z |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
|
Tsai Y.-C.; Yeh C.-H.; Tzen K.-Y.; Ho P.-Y.; Tuan T.-F.; YEONG-SHIAU PU; Cheng A.-L.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-04T02:35:59Z |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
|
Yu-Chieh Tsai;Yeh C.-H.;Tzen K.-Y.;Ho P.-Y.;Tuan T.-F.;Pu Y.-S.;Cheng A.-L.;Cheng J.C.-H.; YU-CHIEH TSAI; Yeh C.-H.; Tzen K.-Y.; Ho P.-Y.; Tuan T.-F.; Pu Y.-S.; Cheng A.-L.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-09-01T01:53:49Z |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
|
Tsai Y.-C.; Yeh C.-H.; Tzen K.-Y.; Ho P.-Y.; Tuan T.-F.; Pu Y.-S.; ANN-LII CHENG; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-18T05:59:06Z |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
|
Tsai Y.-C.; Yeh C.-H.; KAI-YUAN TZEN; Ho P.-Y.; Tuan T.-F.; Pu Y.-S.; Cheng A.-L.; Cheng J.C.-H. |
| 臺大學術典藏 |
2022-09-16T03:41:20Z |
Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFβ signalling
|
Hung C.-T.; Su T.-H.; Chen Y.-T.; Wu Y.-F.; Chen Y.-T.; SUNG-JAN LIN; Lin S.-L.; Yang K.-C. |
| 國立成功大學 |
2024-10 |
Targeting ferroptosis by natural products in pathophysiological conditions
|
Zheng;Daheng;Jin;Shikai;Liu;Pu-Ste;Ye;Jianping;Xie;Xin |
| 臺大學術典藏 |
2020-03-02T07:45:08Z |
Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity
|
Wu H.-T.;Chen S.-C.;Fan K.-C.;Kuo C.-H.;Lin S.-Y.;Shu-Huei Wang;Chang C.-J.;Li H.-Y.; Wu H.-T.; Chen S.-C.; Fan K.-C.; Kuo C.-H.; Lin S.-Y.; SHU-HUEI WANG; Chang C.-J.; Li H.-Y. |
| 臺大學術典藏 |
2020-06-01T06:31:22Z |
Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity
|
Wu H.-T.;Chen S.-C.;Fan K.-C.;Kuo C.-H.;Lin S.-Y.;Wang S.-H.;Chang C.-J.;Hung-Yuan Li; Wu H.-T.; Chen S.-C.; Fan K.-C.; Kuo C.-H.; Lin S.-Y.; Wang S.-H.; Chang C.-J.; HUNG-YUAN LI |
| 臺大學術典藏 |
2020 |
Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity
|
KANG-CHIH FAN; Wu, Hung-Tsung ; Chen, Szu-Chi ; Kuo, Chun-Heng ; Lin, Shin-Yu ; Wang, Shu-Huei ; Chang, Chih-Jen ; Li, Hung-Yuan |
| 臺大學術典藏 |
2021-03-10T03:11:22Z |
Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity
|
Wu H.-T.;Chen S.-C.;Kang-Chih Fan;Kuo C.-H.;Lin S.-Y.;Wang S.-H.;Chang C.-J.;Li H.-Y.; Wu H.-T.; Chen S.-C.; KANG-CHIH FAN; Kuo C.-H.; Lin S.-Y.; Wang S.-H.; Chang C.-J.; Li H.-Y. |
| 臺大學術典藏 |
2021-03-02T06:21:25Z |
Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity
|
Wu H.-T.;Chen S.-C.;Fan K.-C.;Kuo C.-H.;Shin-Yu Lin;Wang S.-H.;Chang C.-J.;Li H.-Y.; Wu H.-T.; Chen S.-C.; Fan K.-C.; Kuo C.-H.; SHIN-YU LIN; Wang S.-H.; Chang C.-J.; Li H.-Y. |
| 國立成功大學 |
2020 |
Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity
|
Wu, H.-T.;Chen, S.-C.;Fan, K.-C.;Kuo, C.-H.;Lin, S.-Y.;Wang, S.-H.;Chang, Chang C.-J.;Li, H.-Y. |
| 臺北醫學大學 |
2015-12 |
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
|
林雨樵 |
| 臺大學術典藏 |
2021-01-12T03:32:01Z |
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
|
Pai C.-H.;Lin S.-R.;Liu C.-H.;Pan S.-Y.;Hsu H.;Chen Y.-T.;Yen C.-T.;Yu I.-S.;Wu H.-L.;Shuei-Liong Lin;Lin S.-W.; Pai C.-H.; Lin S.-R.; Liu C.-H.; Pan S.-Y.; Hsu H.; Chen Y.-T.; Yen C.-T.; Yu I.-S.; Wu H.-L.; SHUEI-LIONG LIN; Lin S.-W. |
| 臺大學術典藏 |
2021-03-11T08:12:06Z |
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
|
Pai, Chen-Hsueh; Lin, Shu-Rung; Liu, Chia-Hao; Pan, Szu-Yu; Hsu, Hao; Chen, Yi-Ting; Yen, Ching-Tzu; Yu, I-Shing; Wu, Hua-Lin; Lin, Shuei-Liong; SHU-WHA LIN |
| 臺大學術典藏 |
2021-08-23T23:47:18Z |
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
|
Pai C.-H.; Lin S.-R.; Liu C.-H.; Pan S.-Y.; Hsu H.; YI-TING CHEN; Yen C.-T.; Yu I.-S.; Wu H.-L.; Lin S.-L.; Lin S.-W. |
| 國立成功大學 |
2020 |
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
|
Pai, C.-H.;Lin, S.-R.;Liu, C.-H.;Pan, S.-Y.;Hsu, Hsu H.;Chen, Y.-T.;Yen, C.-T.;Yu, I.-S.;Wu, H.-L.;Lin, S.-L.;Lin, S.-W. |
